Oculis Holding has concluded subject enrolment for the Phase III DIAMOND-1 and DIAMOND-2 clinical trials of OCS-01 eye drops ...

A new drug application has been submitted for Brimochol™ PF (Tenpoint Therapeutics Ltd.) for the treatment of presbyopia.

Most studies on the combination eye drop brinzolamide and brimonidine (Symbrinza) used the drug three times daily.

Serious side effects from H2 blockers are rare. Like PPIs, they can sometimes cause low B12 levels. Headaches and agitation ...

The patient information guide from Simbrinza says to use it no more than twice a day. I talked to my doctor about this last ...

Tenpoint Therapeutics submitted a new drug application to the FDA for Brimochol PF, an eye drop for presbyopia treatment, ...